Professor Piotr J. Wysocki is a distinguished medical oncologist, translational researcher, and academic leader whose career has shaped modern oncology in Poland. He currently serves as Head of the Department of Clinical Oncology at University Hospital in Krakow and Head of the Faculty of Oncology at the Jagiellonian University–Medical College, one of the oldest and most prestigious medical institutions in Europe. He is internationally recognized for his contributions to breast, gynecologic, and genitourinary oncology, as well as for pioneering metronomic chemotherapy–based therapeutic strategies.
Prof. Wysocki completed his medical degree and PhD in molecular biology at the Poznan University of Medical Sciences in 2000. He subsequently completed specialization in medical oncology in 2007 and received the prestigious life-time title of Professor of Medicine granted by the President of the Republic of Poland in 2012—a recognition awarded to leaders of national scientific excellence. His scientific training includes fellowships at Roswell Park Cancer Institute in Buffalo, New York, and the Princess Margaret Cancer Centre in Toronto, where he deepened his expertise in translational oncology, molecular biology, and early-phase therapeutics.
A prominent figure in Polish and international oncology, Prof. Wysocki served two consecutive terms as President of the Polish Society of Clinical Oncology (PTOK) (2015–2019, 2019–2023). He is a former member of the ASCO International Affairs Committee and a key medical advisor to the Polish Ministry of Health, contributing to the development of the national cancer strategy. He has authored national guidelines for genitourinary cancers and co-authored guidelines in breast cancer, helping standardize oncologic care nationwide.
One of his major achievements is the creation of two specialized early-phase clinical research units in Krakow and Szczecin, significantly expanding Poland’s capacity in phase I investigations and experimental therapeutics. Over the last 15 years, he has served as principal investigator in more than 70 international phase I–III clinical trials, placing him among the most active clinical trialists in the region.
Prof. Wysocki’s research spans translational immunology, molecular oncology, and innovative therapeutic approaches for heavily pretreated cancer patients. He is a global pioneer in therapeutic Immunopheresis, having conducted first-in-human studies exploring apheresis-based immunomodulation for solid tumors and the mitigation of immune-related adverse events. His clinical program integrates chemo-endocrine, chemo-targeted, and metronomic polychemotherapy strategies, with a strong emphasis on improving outcomes and tolerability for advanced-stage patients.
Throughout his academic career, Prof. Wysocki has supervised multiple PhD theses, trained numerous oncology residents, and delivered more than 1,000 lectures at national and international conferences, symposia, and educational programs. He has authored over 100 peer-reviewed publications in clinical, translational, and preclinical oncology .
Prof. Wysocki continues to play a central role in shaping oncology education, research, and clinical innovation in Poland, while contributing actively to global oncology discourse.
He is a Member of the Editorial Board of OncoDaily.